KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Return on Equity: 2019-2025

Historic Return on Equity for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to 0.24%.

  • Esperion Therapeutics' Return on Equity rose 13.00% to 0.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.24%, marking a year-over-year increase of 13.00%. This contributed to the annual value of 0.01% for FY2024, which is 54.00% down from last year.
  • Esperion Therapeutics' Return on Equity amounted to 0.24% in Q3 2025, which was down 2.02% from 0.25% recorded in Q2 2025.
  • Esperion Therapeutics' 5-year Return on Equity high stood at 1.13% for Q2 2021, and its period low was 0.01% during Q4 2024.
  • Its 3-year average for Return on Equity is 0.34%, with a median of 0.25% in 2024.
  • Over the last 5 years, Esperion Therapeutics' Return on Equity had its largest YoY gain of 607bps in 2021, and its largest YoY loss of 1,675bps in 2021.
  • Esperion Therapeutics' Return on Equity (Quarterly) stood at 0.98% in 2021, then fell by 21bps to 0.76% in 2022, then fell by 27bps to 0.50% in 2023, then tumbled by 48bps to 0.01% in 2024, then grew by 13bps to 0.24% in 2025.
  • Its Return on Equity stands at 0.24% for Q3 2025, versus 0.25% for Q2 2025 and 0.26% for Q1 2025.